The latest in eye surgery is the Visian Implantable Contact Lens or ICL, which was originally designed for patients who were not candidates for LASIK surgery due to high myopic (nearsighted) prescriptions. But the success of the Visian ICL implant has resulted in an increased interest from candidates who are considered good choices for LASIK.
The Visian ICL is an Implantable Collamer Lens that works with the eye to correct patients with moderate to severe nearsightedness. Unlike traditional contact lenses that go on the surface of the eye, the Visian ICL is positioned inside the eye between the iris and the natural lens where it stays indefinitely. With a satisfaction rate of over 99% many of our patients choose the Visian ICL to get the freedom from their contact lenses and glasses that they’ve always desired.
The Visian ICL is the procedure of choice for patients who need and expect higher quality results in performance and safety. In fact, the US Military has embraced the Visian ICL because of the reliable visual clarity it achieves. Much like the recovery with laser vision procedures, results are immediate with the Visian ICL.
Limitations of LASIK – Advantages of an ICL
Ranges of nearsightedness – Most surgeons agree that LASIK should not be performed on anyone who has a prescription over -10.0. The ICL can be used for anyone between the ages of 18 and 45 with -5.00 to -20.00 diopters of nearsightedness.
Glare and Halos – Changing the natural curve of the cornea with LASIK may induce aberrations that can lead to glare and halos in some patients. Glare and halos are less common with ICL’s because they cause less aberration in the eye.
Medical Contraindications – Patients with lupus, Crohn’s disease, rheumatoid disease and dry eye syndrome are at a higher risk for complications with LASIK procedures, but are at minimal risk of worsening conditions after an ICL.
Why choose Clear Advantage for your Visian ICL procedure?
Dr. N. Timothy Peters is the first surgeon in New Hampshire to be certified to implant the Visian ICL. There have been over a quarter of a million Visian ICL procedures performed worldwide.
Clinical Trial of Visian ICL for Moderate to High Myopia: Three-Year Follow-Up
In the 2004 ICL clinical trial three-year follow-up reviewed by the FDA "support the safety, efficacy, and predictability of Visian ICL surgery to treat moderate to high myopic errors."1
The three-year data, based on the assessment of 526 eyes of 294 patients, also produced the following refractive results:
- 99 percent of patients were satisfied/very satisfied with their results.
- 98.3 percent of patients had uncorrected visual acuity of 20/40 or better.
- Once vision was corrected, the correction was stable and did not change over the follow up period.
- Additionally, the incidence of glare, halos, double vision, night vision problems, and night driving difficulties remained unchanged from before surgery.